Status:
COMPLETED
6x3 Crossover, Bioavailability, Safety and Tolerability Among Different Eutropin Formulations in Healthy Volunteers
Lead Sponsor:
LG Chem
Conditions:
Bioavailability, Safety and Tolerability Among Different Eutropin Formulations in Healthy Volunteers
Eligibility:
All Genders
19-40 years
Phase:
PHASE1
Brief Summary
A Randomized, Open Label, Single Subcutaneous Dose 6x3 Crossover Study to Investigate the Relative Bioavailability, Safety and Tolerability among Different Eutropin Formulations in Healthy Volunteers
Eligibility Criteria
Inclusion
- Healthy volunteers between the ages of 19 or more and less than 40 years (19 =\< age \< 40) on the day of screening
- Negative findings in serum / urine hCG test or Subjects who are not pregnant or lactating in women
Exclusion
- Administered other drug(s) in other clinical study within 180 days prior to the day of screening
Key Trial Info
Start Date :
September 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 2 2020
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04085224
Start Date
September 10 2019
End Date
January 2 2020
Last Update
March 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea